



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |           |   |
|--|-----------|---|
| <b>(51) International Patent Classification <sup>5</sup> :</b><br>C07C 251/58, C07D 295/08<br>C07C 295/12, 249/12<br>A61K 31/15  | <b>A1</b> | <b>(11) International Publication Number:</b> <b>WO 90/04584</b><br><br><b>(43) International Publication Date:</b> 3 May 1990 (03.05.90)   |
| <b>(21) International Application Number:</b> PCT/HU89/00048<br><b>(22) International Filing Date:</b> 19 October 1989 (19.10.89)<br><b>(30) Priority data:</b><br>5405/88 20 October 1988 (20.10.88) HU<br><b>(71) Applicant (for all designated States except US):</b> BIOREX KUTATÓ FEJLESZTŐ KFT. [HU/HU]; Medve u. 25-29, H-1027 Budapest (HU).<br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only) :</b> LITERÁTI NAGY, Péter [HU/HU]; VII. u. 38, H-1172 Budapest (HU). BALÁZS, Béla [HU/HU]; Kaptárkő u. 2, H-1118 Budapest (HU). BOROSS, Mária [HU/HU]; Pauler u. 4, H-1013 Budapest (HU). SZILBEREKY, Jenő [HU/HU]; Szamos u. 7, H-1122 Budapest (HU). ZSILA, Gizella [HU/HU]; Jász u. 94, H-1131 Budapest (HU). ÁBRAHÁM, Lajos [HU/HU]; Vécsei u. 4, H-1054 Budapest (HU). BLASKÓ, György [HU/HU]; Zöldlomb u. 32, H-1025 Budapest (HU). GACHÁLYI, Béla [HU/HU];  |           | Damjanich u. 26, H-1071 Budapest (HU). ALMÁSI, Attila [HU/HU]; Izabella u. 48, H-1064 Budapest (HU). NÉMETH, Gábor [HU/HU]; Zsókavár út 48, H-1157 Budapest (HU).<br><br><b>(74) Agent:</b> S.B.G. & K.; Dalszínház u. 10, H-1061 Budapest VI (HU).<br><br><b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), SU, US.<br><br><b>Published</b><br><i>With international search report.</i> |
| <b>(54) Title:</b> NOVEL O-(3-AMINO-2-HYDROXYPROPYL)-HYDROXIMIC ACID HALIDES AND PROCESS FOR PREPARING THE SAME<br><br><b>(57) Abstract</b><br><br>The present invention relates to novel hydroximic acid halides, the preparation of the same, pharmaceutical compositions containing the above novel compounds as active ingredients as well as the use of the said compounds in the therapy of diabetic angiopathy. The novel hydroximic acid derivatives are illustrated by the general formula (I), wherein X is halo, such as fluoro, chloro, bromo and iodo; R <sup>1</sup> is hydrogen or C <sub>1-5</sub> alkyl; R <sup>2</sup> is C <sub>1-5</sub> alkyl, C <sub>5-7</sub> cycloalkyl or phenyl optionally substituted with hydroxy, or R <sup>1</sup> and R <sup>2</sup> , when taken together with the adjacent nitrogen, form a 5 to 8 membered ring optionally containing additional nitrogen and/or oxygen atom, which ring may also be condensed with a benzene ring; R <sup>3</sup> is hydrogen, phenyl, naphthyl or piridyl optionally substituted with one or more halo or alkoxy; R <sup>4</sup> is hydrogen or phenyl; R <sup>5</sup> is hydrogen or phenyl; m is 0, 1 or 2 and n is 0, 1 or 2. |           |   |

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                              |    |  |    |                          |
|----|------------------------------|----|--|----|--------------------------|
| AT | Austria                      | ES | Spain                                    | MG | Madagascar               |
| AU | Australia                    | FI | Finland                                  | ML | Mali                     |
| BB | Barbados                     | FR | France                                   | MR | Mauritania               |
| BE | Belgium                      | GA | Gabon                                    | MW | Malawi                   |
| BF | Burkina Faso                 | GB | United Kingdom                           | NL | Netherlands              |
| BG | Bulgaria                     | HU | Hungary                                  | NO | Norway                   |
| BJ | Benin                        | IT | Italy                                    | RO | Romania                  |
| BR | Brazil                       | JP | Japan                                    | SD | Sudan                    |
| CA | Canada                       | KP | Democratic People's Republic<br>of Korea | SE | Sweden                   |
| CF | Central African Republic     | KR | Republic of Korea                        | SN | Senegal                  |
| CG | Congo                        | LI | Liechtenstein                            | SU | Soviet Union             |
| CH | Switzerland                  | LK | Sri Lanka                                | TD | Chad                     |
| CM | Cameroon                     | LU | Luxembourg                               | TG | Togo                     |
| DE | Germany, Federal Republic of | MC | Monaco                                   | US | United States of America |
| DK | Denmark                      |    |  |    |                          |

-1-

Novel O-(3-amino-2-hydroxypropyl)-hydroximic acid halides and process for preparing the same.

#### Technical field

The present invention relates to novel hydroximic acid  
5 halides, the preparation of the same, pharmaceutical compositions containing the above novel compounds as active ingredient as well as the use of the said compounds in the therapy of diabetic angiopathy.

#### Background art

10 One of the most frequent metabolism diseases is diabetes mellitus, the main symptom of which is the disturbance of the balance of carbohydrate metabolism in the organism. Diabetes mellitus is often accompanied by pathological vascular deformations, e.g. vasoconstrictions in the limbs, pathological  
15 deformation of the eyeground vessels, etc. Though, in addition to insulin a large number of effective drugs are known, in the field of the treatment of diabetic angiopathy associated with the basic disease, results provided by the commercially available compositions are quite poor. This situation  
20 is caused by the phenomenon that diabetes mellitus results in changes of the vascular adrenerg receptors, and consequently, medical treatment with the commercially available drugs results in adrenerg reaction different from those taking place in the blood vessels of non-diabetic patients. (Nature

-2-

New Biology, 243, No. 130, 276 /1973/; Szemészet, 111, 23 /1974/; Endocrinology, 93, 752 /1973/). The adrenergic receptors of blood vessels in diabetic patients undergo a transformation into beta receptors due to the quantitative increase of the metabolism. For the receptor transformation, the release of a modulator is responsible (Amer.J.Physiol., 218, 869 /1970/). After addition of the modulator to the alpha organ the alpha agonists will not be active any more as the receptor is transformed into beta.

5 The original alpha sensibility may be recovered by adding a special beta blocking agent into the organism.

In case of qualitative alteration of the metabolism in model or human in vivo diabetes the alpha agonists, e.g. noradrenalin, remain effective, this effect, however, may be compensated by the addition of beta blocking agents. This is the first functional change which is detectable in diabetes, e.g. by addition of Alloxane (Hexahydropyrimidin-tetraon), 24 hours after the administration. In case of diabetes an imperfect alpha-beta receptor transformation - possibly due to the formation of an alternative, so-called "Falsch" modulator - serves as starting point of the pathological changes.

#### Disclosure of the invention

It has been found that the novel compounds of the formula (I) wherein

25 X is halo, such as fluoro, chloro, bromo and iodo.  
R<sup>1</sup> is hydrogen or C<sub>1-5</sub> alkyl,

- 3 -

R<sup>2</sup> is C<sub>1-5</sub> alkyl, C<sub>5-7</sub> cycloalkyl or phenyl each optionally being substituted with hydroxy, and

R<sup>1</sup> and R<sup>2</sup>, when taken together with the adjacent nitrogen atom, form a 5-8 membered ring optionally containing addi-

5 tional nitrogen and/or oxygen atom, which ring may also be condensed with a benzene ring, R<sup>3</sup> is hydrogen, phenyl, naphthyl or piridyl optionally substituted with one or more halo or alkoxy,

R<sup>4</sup> is hydrogen or phenyl,

10 R<sup>5</sup> is hydrogen or phenyl,

m is the integer of 0, 1 or 2 and

n is the integer of 0, 1 or 2,

essentially do not influence, or only slightly, the adrenerg reactions of the healthy blood vessels, but show a strong

15 effect on the adrenerg receptors deformed by the diabetes mellitus. This effect appears in the first line as a selective beta-blocking effect, consequently, the compounds of the general formula (I) are useful in medical influencing of diabetic angiopathy.

20 The common beta-blocking agents <Inderal, 1-(methyl-ethyl-amino)-3-(1-naphtalenyloxy)-2-propanol, Visken, 4,5-dihydro-2-(5-methyl-2-/1-methyl-ethyl-phenoxy/-methyl)-1H-imidazol> are contraindicated in the therapy of diabetic angiopathy.

25 Diabetes selective adrenerg receptor blocking compounds are described in Hungarian Patent No. 177,578, "Process for preparing novel OF-(3-amino-2-hydroxypropyl)-amidoxim derivatives". All other object of the invention is the process for prepar-

- 4 -

ing the compounds of the general formula (I) and the salts thereof. According to the process

a) an aldoxim of the general formula (III) wherein  $R^3$ ,  $R^4$ ,  $R^5$ ,  $m$  and  $n$  are as defined above, is reacted in the presence  
5 of a base with an amine of the general formula (IV/A) and (IV/B), resp., wherein  $R^1$  and  $R^2$  are as defined above and  $X$  is halo, or

b) an aldoxim of the general formula (III), wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $m$  and  $n$  are as specified above, is reacted with epichlorohydrine and the aldoxim derivative of the general formula  
10 (VI) thus obtained is reacted with an amine of the general formula (V), wherein  $R^1$  and  $R^2$  are as specified above, to obtain the aldoxim derivatives of the general formula (VII), and

15 the compounds of the general formula (VII) according to the above processes a) or b) are reacted with inorganic acid halides, or other halogenating agents, e.g.  $POX_3$ ,  $SOX_3$ ,  $PX_5$  - wherein  $X$  is halo - to obtain the halo derivatives of the general formula (VIII), and by replacing the halo atom on the  
20 aliphatic chain thereof with hydroxy, the compounds of the general formula (I) are obtained, or

c) an amidoxim derivative of the general formula (II) is diazotized in the presence of  $NaNO_2$  and  $HX$  - wherein  $X$  is halo - and subjected to "boiling away" reaction.

25 If desired, the free bases of the general formula (I) may be transformed to acid addition salts by reacting with organic or inorganic acids, or the compounds obtained as salts may be transformed into the free bases.

**SUBSTITUTE SHEET**

- 5 -

According to a preferred embodiment of the process a) the reaction is carried out in aqueous medium, in an aqueous organic solvent, such as aqueous alcohol or in organic solvents, preferably at a temperature of 0 to 140°C.

- 5 According to an other embodiment of the process variant a) the salts of the aldoximes of the general formula (III) are formed in dry alcoholic medium with alkali alcoholates, and subsequently the solutions of the amines of the general formulae (IV/A) and (IV/B), resp., in alcohol are added  
10 thereto. The reaction is preferably carried out at a temperature of 0 to 100°C under stirring.

- According to a still another embodiment of the process variant a) the salts of the aldoximes of the general formula (III) are formed in a solvent non-miscible with water, such  
15 as benzene, toluene, xylene, with alkali hydroxides, preferably sodium or potassium hydroxide. The salt forming is carried out at the boiling temperature of the solvent, and the water forming during the reaction is continuously removed by azeotropic distillation, followed by the addition of the  
20 solution of the compounds of the general formulae (IV/A) and (IV/B), resp.

- According to an other embodiment of the process variant a) the reaction is carried out in aqueous medium, by adding to the compounds (IV/A) or (IV/B) the aqueous-alkaline solution  
25 or suspension of the aldoximes under stirring.

The reaction is carried out preferably at a temperature of 0 to 60°C and the aldoxim is added to the reaction mixture in

**SUBSTITUTE SHEET**

- 6 -

the form of a solution or suspension of a temperature of 5 to 20°C in aqueous alkali solution. The reaction may also be carried out in a mixture of water and an organic solvent, wherein to the solution of the compound of the general formula (IV/A) or (IV/B) in alcohol or dioxane the aqueous-alkaline solution or suspension of the aldoxim is added dropwise. The addition may also be accomplished in reversed order, i.e. to the aqueous-alkaline solution or suspension of the aldoxim is added the other reaction partner.

According to process variant b) the aldoxim of the general formula (III) is reacted with epichlorohydrine in the presence of a base. If desired, the epoxy compound obtained during the reaction may be isolated, it is preferred, however, to carry out the reaction in one synthesis step, without isolating the intermediate, in aqueous medium or in an organic solvent, aqueous organic solvent, or in a two-phase system, at a temperature of -10 to + 60°C, by adding the reagent in one or two portions or dropwise. The order of addition may be reversed, i.e. either the alkaline solution or suspension of the aldoxim is added to the epichlorohydrine, or the aldoxim is added to the mixture of the epichlorohydrine and base. If desired, the intermediate of the formula (VI) may be separated by extracting with a solvent non-miscible with water. It is more preferred, however, to react the compound of the general formula (VI) without isolation with the corresponding amine.

The process variant b) may also be carried out in dry sol-

SUBSTITUTE SHEET



- 7 -

vents, preferably dry alcohols. In this case the alkali metal salt of the aldoxim is formed, suitably by dissolving the aldoxim in a solution of alkali alcoholate in alcohol. Following the addition of the epichlorohydrine, the reaction mixture is allowed to stand for 1 to 5 days at a temperature of 0 to 20°C and subsequently the reaction is carried on by the addition of the corresponding amine, at ambient temperature or by heating the mixture. Besides the alcohol, as dry solvent also other organic solvents, e.g. acetone, dimethyl sulfoxide, dimethyl formamide, etc. or the mixtures thereof may be used.

The compounds of the general formula (VII) obtained according to the processes a) or b) can be isolated by methods known per se. If aqueous medium is used, the isolation is generally accomplished by extraction, followed by drying and evaporating the solvent. Subsequently the aldoxim derivative of the formula (VII) is boiled with the inorganic acid halides, such as  $\text{PCl}_5$ ,  $\text{SOCl}_2$ ,  $\text{POCl}_3$  for 1 to 5 hours in the presence or absence of a solvent, preferably halogenated solvents, such as  $\text{CHCl}_3$ . The compounds of the general formula (VII) thus obtained can be isolated by making the mixture alkaline with aqueous alkali, followed by extraction.

The compound of the general formula (VIII) is a hydroximic acid halogenated in the chain. It has been found that the halo moiety thereof will not enter into nucleophilic substitution reaction under the reaction conditions, and accordingly, the formation of the OH group will be accomplished selec-

- 8 -

tively, in one step by aqueous-alkaline hydrolysis at a temperature of 0 to 100°C, using preferably alkali hydroxides or other metal hydroxides, e.g. silver hydroxide, or in two steps, first forming an ester moiety suitably with the alkali salts of lower carboxylic acids followed by the hydrolysis to obtain the compounds of the general formula (I).

The reaction conditions of process variant c) are selected so that the temperature is maintained between -5 and +10°C and thus, also the "boiling away" reaction takes place.

10 Preferably the reaction is carried out in water, and the intermediate diazonium salt is not isolated but also the "boiling away" reaction is carried out by selecting suitable reaction conditions thus obtaining the compounds of the general formula (I).

15 The reaction products can be separated from the reaction mixture by methods known per se, e.g by crystallisation and extraction, when using water as reaction medium. When organic solvents are used, crystallisation or evaporation followed by washing with water and extraction is applied. The products  
20 may be isolated in the form of salts thereof, or from the isolated bases salts may be formed by using molar equivalent of mineral or organic acids, preferably pharmaceutically acceptable acids, or, if desired, from the salts the free bases can be obtained.

25 The general beta-blocking effect of the compounds of the general formula (I) was studied on anaesthetised cats. In these tests besides registering the blood pressure and pulse

- 9 -

rate, also the effect of the test materials on the left ventricular contractility was studied. As reference material Inderal <1-isopropylamino-3-(naphtyloxy)-propan-2-ol> was used.

5     The beta-blocking effect of the compounds according to the present invention was tested on rat aorta spiral and/or ring  
preparate <J.Pharmacol.Exp.Therap. 158, 531 (1967)>. The  
experimental diabetes was induced with Streptosotocin  
10     <2-(3-nitroso-3-methylureido)-2-deoxy-D-glucose>. The reac-  
tion was evaluated as positive when the alpha stimulating  
effect of the noradrenalin on the control preparate, i.e.  
that having not been treated with Streptosotocin, was not  
influenced, but protected on the diabetic aorta. In the  
tests carried out with the compounds according to the present  
15     invention a general selective effect occurred, manifesting in  
case of diabetic tests in a strong, in case of normal tests  
in the absence of or in the presence of only a slight beta-  
blocking effect.

Experiments were carried out to study whether on the aorta  
20     spiral preparates of diabetic animals treated with Streptosoto-  
cin the Inderal protects the contractions induced by norad-  
renalin. As control, animals previously not treated with  
Streptosotocin were used. The results obtained essentially  
conformed to those known from the literature <Amer.J.Physiol.,  
218, 869 (1970)>, i.e. the alpha stimulating effect of nor-  
adrenalin was protected by the Inderal in diabetic tests,  
but not in the normal tests. (Endocrinology, Vol. 93, No.

- 10 -

3, Sept. 1973).

It has been found that the compounds of the general formula (I) showed a slight general beta-blocking effect. Compared with the control beta-blocking Inderal the compounds tested showed an effect of two orders of magnitude less in the inhibition of the beta-blocking D,L-1-(3,4-dihydroxy-phenyl)-2-isopropylamino-ethanol.

At the same time the compounds of the general formula (I) produced a significant parallel shift to the right of the noradrenalin dose-response curve in diabetic rat aorta ring (and/or spiral) in the order of magnitude of the effect of Inderal. The dose of Inderal was 0,5 micrograms/ml, while the dose of the compounds of the general formula (I) was 1,0 microgram/ml.

Accordingly, the O-(3-amino-2-hydroxypropyl)-hydroximic acid halides of the general formula (I) may preferably be used in the therapy of any kind of diabetic micro- and macroangiopathy, especially of diabetic retinopathy and diabetic nephropathy in case of diabetes mellitus. The above compounds can be used per se or in the form of pharmaceutical preparations. The above treatment and pharmaceutical compositions also form the object of the present application. The pharmaceutical compositions of the present invention can be used for prevention, for treatment in the active phase of the disease as well as in acute cases.

The hydroximic acid halides of the general formula (I) are effective exclusively on patients in the stadium of formation

- 11 -

of diabetes, and are ineffective on non-diabetic persons.

Best mode of carrying out the invention

Preferred are those compounds of the general formula (I) wherein X is chloro, m and n are each 0, R<sup>3</sup> is 3,4-  
5 dimethoxybenzyl, piridyl, naphthyl or indolyl and R<sup>1</sup> is and R<sup>2</sup> is isopropyl, 2-hydroxyethyl or t-butyl, or R<sup>1</sup> and R<sup>2</sup> together form pentamethylene. Especially preferred active compounds are those mentioned in the following examples.

The invention is further illustrated in the following exam-  
10 ples. It is to be understood, however, that the scope of protection is not limited to the matter disclosed in the examples any way.

Example 1.

2,3 g of sodium were dissolved in 200 ml of abs. ethanol and  
15 then 12,1 g of benzaldoxim were added. At boiling temperature the solution of 3-piperidino-2-hydroxy-1-chloropropane prepared from 9,3 g epichlorohydrine and 8,5 g of piperidine in 50 ml of abs. ethanol by methods known per se was added dropwise. The reaction mixture was boiled for 8 hours under  
20 reflux, the precipitated salt was filtered at room temperature and the solvent was distilled off in vacuo. To the residue 100 ml of 5% sodium hydroxide were added and the oily product was extracted with benzene. After drying and evaporating the benzene extract 8,2 g of O-(3-piperidino-2-hy-

- 12 -

droxy-1-propyl)-benzaloxim was obtained. The hydrochloride of the product was separated from the isopropanol solution thereof by introducing gaseous hydrochloric acid into or adding hydrochloric acid in ethanol to the solution. Mp.

5 137°C (from isopropanol).

Analysis based on  $C_{15}H_{23}ClN_2O_2$ : Mw. 298,81

Calculated: C 60,29, H 7,76, N 9,37, Cl 11,86;

Found: C 60,35, H 8,00, N 9,25, Cl 11,90%.

2,98 g of O-(3-piperidino-2-hydroxy-1-propyl)-benzaloxim  
10 were boiled in 20 ml of thionyl chloride for 3 hours. The O-(3-piperidino-2-chloro-1-propyl)-benzhydroximic acid chloride was separated by adding about 100 ml of 20 % aqueous base until pH = 11 followed by extraction with chloroform. The chloroform extract was dried over sodium sulfate and evapo-  
15 rated. The oil-like product can be transformed into the compound of the general formula by different ways:

a) 3,4 g of oily product were hydrolized with 20 ml of 20% NaOH at 55 to 60°C for 2 hours under stirring, extracted with benzene, the benzene solution was dried with solid drying  
20 agent and subsequently evaporated. To the residue 50 ml of hydrochloric acid in ethyl acetate was added. Under stirring the hydrochloride of the O-(3-piperidino-2-hydroxy-1-propyl)-benzhydroximic acid chloride precipitated.

Yield: 2,1 g. NMR (base,  $CDCl_3$ ): 7,4-8,0 m (5H); 3,9-4,4 m  
25 (3H); 2,2-2,8 m (6H); 1,3-1,8 m (6H); 3,5 s (OH).

Mp. 140-142°C (from isopropanol)

Analysis: based on  $C_{15}H_{22}Cl_2N_2O_2$ :

- 13 -

Calculated: C 54,22, H 6,37, N 8,43, Cl 21,14;

Found: C 53,12, H 6,26, N 8,19, Cl 20,84%.

b) 0,81 g (4,74 mmoles) of  $\text{AgNO}_3$  were dissolved in 4 ml of water and under stirring 0,19 g of NaOH (4,74 mmoles) in 3 ml  
5 of water was added thereto dropwise. The aqueous suspension of the AgOH precipitate was stirred with 1,5 g (4,74 mmoles) of O-(3-piperidino-2-chloro-1-propyl)-benzhydroximic acid chloride at 50°C for 3 hours. Then the suspension was extracted with benzene, the benzene layer was dried with sodium  
10 sulfate, filtered, evaporated and subjected to the salt forming step described in process a). Yield 95%. The physical data of the end product are identical with those in process a).

c) 3,0 g (9,49 mmoles) of  
15 O-(3-piperidino-2-chloro-1-propyl)-benzhydroximic acid chloride were dissolved in 10 ml of ethanol, under stirring 0,86 g ( $1,05 \cdot 10^{-2}$  moles) of sodium acetate in 15 ml of water were added and the mixture was stirred for 3 hours at 50°C. The reaction mixture was evaporated in vacuo and the residue was  
20 extracted with benzene. The benzene extract was dried over sodium sulfate and evaporated, thus providing 2,12 g of oily O-(3-piperidino-2-acetoxy-1-propyl)-benzhydroximic acid chloride. The ester thus obtained was dissolved in 20 ml of ethanol followed by the addition of 20 ml of water. 0,25 g of  
25 NaOH in 20 ml of water were added to the mixture and stirred at 40°C for one hour, extracted with benzene, the benzene extract was dried with sodium sulfate and evaporated. From

- 14 -

the residue salt was formed according to the method in process a). Yield 90%. The quality of the product was identical with that of process a).

#### Example 2.

5      Following the process as described in Example 1 but starting from 3-piridyl-aldoxim and 3-piperidino-2-hydroxy-1-chloropropane the O-(3-piperidino-2-hydroxy-1-propyl)-3-piridyl-aldoxim was prepared, which was reacted with thionyl chloride according to Example 1. After removing the thionyl chloride  
10 by evaporation, isopropanol was added to the residue thus crystallising the O-(3-piperidino-2-chloro-1-propyl)-3-piridyl-hydroximic acid chloride in the form of the dihydrochloride. Mp. 142°C ( from isopropanol). Yield 85 %.

Analysis based on  $C_{14}H_{21}Cl_4N_3O$ :      Mw = 389,15

15      Calculated: C 43,21, H 5,44, N 10,79, Cl 36,44;

Found:      C 42,97, H 5,62, N 10,59, Cl 36,80%.

According to another mode of preparation the O-(-3-piperidino-2-chloro-1-propyl)-3-piridyl-hydroximic acid chloride dihydrochloride obtained as above was not isolated,  
20 instead, to the evaporation residue 10 % NaOH was added until a pH of 11 in accordance with Example 1 and the mixture thus obtained was extracted with chloroform. The chloroform layer was dried, evaporated and subsequently hydrolyzed by using any of the processes a), b) and c) of Example 1. The hydrolysis mixture was extracted with benzene, dried with sodium  
25 sulfate and evaporated. The residue was dissolved in acetone



- 15 -

followed by the addition of maleic acid and isolating the O-(3-piperidino-2-hydroxy-1-propyl)-3-pyridyl-hydroxamic acid chloride maleate thus obtained by filtering.

NMR (base,  $\text{CDCl}_3$ ): 9,03, 8,59, 8,00, 7,1-7,4, 3,84 s (3H),

5 1,1-1,8 (6H), 5,28 s (OH).

Mp. 125°C (from aceton). Yield 65 %.

Analysis based on  $\text{C}_{18}\text{H}_{24}\text{ClN}_3\text{O}_6$ : Mw. = 413,79

Calculated: C 52,24, H 5,84, N 10,15, Cl 8,55;

Found: C 52,26, H 5,99, N 9,87, Cl 8,46%.

### 10 Example 3

To 3,5 g (10 mmoles) of O-(3-piperidino-2-hydroxy-1-propyl)-benzamidoxim dihydrochloride 40 mmoles of hydrogen chloride (in 37 % form) was added at 5°C under vigorous stirring.

After the addition of 5 ml of dioxane the mixture was cooled  
15 to 0°C by using salt-ice. At the same temperature a solution of 1,38 g (20 mmoles) of  $\text{NaNO}_2$  in 6 ml water was added dropwise during a period of 1,5 hours followed by intensive stirring for 4 hours at ambient temperature. The acidic reaction mixture was made alkaline by the addition of 10 %  
20 sodium hydroxide until a pH of 11 and then extracted with 80 to 100 ml of benzene. The benzene layer was dried over sodium sulfate and evaporated. From the residue the hydrochloride of the O-(3-piperidino-2-hydroxy-1-propyl)-benzhydroxamic acid  
25 chloride was formed by the addition of a saturated solution of hydrochloric acid in ethyl acetate and isolated by filtering. Mp. 139-141°C.

- 16 -

Analysis based on  $C_{15}H_{22}Cl_2N_2O_2$ : Mw = 333,25

Calculated: C 54,22, H 6,37, N 8,43, Cl 21,14;

Found: C 54,62, H 6,16, N 8,09, Cl 20,71%.

#### Example 4

- 5 The process described in Example 3 was followed but instead of hydrochloric acid, hydrogen bromide was used as hydrogen halide, thus obtaining the O-(3-piperidino-2-hydroxy-1-propyl)-benzhydroximic acid bromide hydrochloride. Yield 27 %.  
Mp. 138°C (from isopropanol)

10 Analysis based on  $C_{15}H_{22}BrClN_2O_2$ : Mw = 377,71

Calculated: C 47,63, H 5,87, N 7,41;

Found: C 47,60, H 6,19, N 7,50%.

#### Example 5

- Following the process as described in Example 3 O-(3-  
15 piperidino-2-hydroxy-1-propyl)-nicotinic acid amidoxim dihydrochloride was diazotized, by using hydrochloric acid as hydrogen halide. Following the diazotizing and "boiling away" reaction from the O-(3-piperidino-2-hydroxy-propyl)-3-pyridyl-hydroximic acid chloride the maleate was formed in dry  
20 organic solvent by adding molar equivalent of maleic acid, and then separated. Mp. 125°C (from acetone). Yield 58 %.

Analysis based on  $C_{18}H_{24}ClN_3O_6$ : Mw = 413,79

Calculated: C 52,24, H 5,84, N 10,15, Cl 8,55;

Found: C 52,26, H 5,99, N 9,87, Cl 8,46%.

- 17 -

LD<sub>50</sub>: 110 mg/kg iv. on Wistar rats.

#### Example 6

Following the process as described in Example 5 but using hydrogen bromide instead of the hydrochloric acid as hydrogen  
5 halide, the O-(3-piperidino-2-chloro-1-propyl)-3-pyridyl-hydroxamic acid bromide maleate was obtained. Yield: 58 %.  
Mp. 117°C (from acetone)

Analysis based on C<sub>18</sub>H<sub>24</sub>BrN<sub>3</sub>O<sub>6</sub>: Mw = 457,25  
Calculated: C 47,36, H 5,21, N 9,16, Br 17,13;  
10 Found: C 47,67, H 5,31, N 8,80, Br 16,78%.

#### Example 7

Following the process as described in Example 3 but using O-(3-piperidino-2-hydroxy-1-propyl)-3,3-diphenyl-propionic  
acid hydroxamic acid dihydrochloride as amidoxim component in  
15 the diazotizing reaction, the O-(3-piperidino-2-hydroxy-1-propyl)-3,3-diphenyl-propionic acid hydroxamic acid  
dihydrochloride was obtained.

Yield: 30 %. Mp. 149-152°C (from isopropanol).  
NMR (base, DMSO-d<sub>6</sub>): 7,1-7,6 m (10H), 4,5 t (14), 3,34 d (2H),  
20 J = 7,5 Hz, 3,9 br s (3H), 2,3-3,0 m (6H), 1,3-1,9 m (6H), OH  
shaded.

Analysis based on C<sub>23</sub>H<sub>30</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub>: Mw = 437,40  
Calculated: C 63,15, H 6,51, N 6,40, Cl 16,21;  
Found: C 63,50, H 6,79, N 6,31, Cl 16,47%.

- 18 -

## Example 8

Following the process as described in Example 3 but using  
O-(3-diethylamino-2-hydroxy-1-propyl)-3,3-diphenyl-propionic  
acid amidoxim dihydrochloride as starting amidoxim component,  
5 the O-(3-diethylamino-2-hydroxy-1-propyl)-3,3-diphenyl-propionic  
acid hydroximic acid chloride dihydrochloride was obtained.  
Yield: 32 %. Mp. 155°C (from isopropanol).

Analysis based on  $C_{22}H_{30}Cl_2N_2O_2$ : Mw = 425,40

Calculated: C 62,11, H 7,10, N 7,52, Cl 16,66;

10 Found: C 62,10, H 6,98, N 7,45, Cl 17,00%.

## Example 9

Following the process as described in Example 3 but using  
O-(3-isopropylamino-2-hydroxy-1-propyl)-benzamidoxim dihydro-  
chloride as starting amidoxim component, the O-(3-  
15 isopropylamino-2-hydroxy-1-propyl)-benzhydroximic acid hydro-  
chloride was prepared. Yield 12 %. Mp. 122°C (from isopropanol).

Analysis based on  $C_{13}H_{20}Cl_2N_2O_2$ : Mw = 307,22

Calculated: C 50,82, H 6,56, N 9,11, Cl 23,08;

20 Found: C 51,12, H 6,58, N 9,05, Cl 22,89%.

- 19 -

## Claims

1. Hydroximic acid derivatives of the general formula (I)  
and the salts thereof wherein

X is halo, such as fluoro, chloro, bromo and iodo,

5 R<sup>1</sup> is hydrogen or C<sub>1-5</sub> alkyl,

R<sup>2</sup> is C<sub>1-5</sub> alkyl, C<sub>5-7</sub> cycloalkyl or phenyl optionally  
substituted with hydroxy, or

R<sup>1</sup> and R<sup>2</sup>, when taken together with the adjacent nitrogen,  
form a 5 to 8 membered ring optionally containing additional  
10 nitrogen and/or oxygen atom, which ring may also be condensed  
with a benzene ring,

R<sup>3</sup> is hydrogen, phenyl, naphtyl or piridyl optionally  
substituted with one or more halo or alkoxy,

R<sup>4</sup> is hydrogen or phenyl,

15 R<sup>5</sup> is hydrogen or phenyl,

m is 0, 1 or 2 and

n is 0, 1 or 2.

2. Process for preparing the hydroximic acid derivatives of  
the formula (I) and the salts thereof defined in claim 1  
20 characterized in that

a) an aldoxim of the general formula (III) wherein R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>,  
m and n are as defined in claim 1, is reacted in the presence  
of a base with an amine of the formula (IV/A) or (IV/B),  
wherein R<sup>1</sup> and R<sup>2</sup> are as defined in claim 1 and X is halo, or

- 20 -

b) an aldoxim of the general formula (III) wherein  $R^3$ ,  $R^4$ ,  $R^5$ , m and n are as defined in claim 1, is reacted with epichlorohydrine and the aldoxim of the general formula (VI) thus obtained is reacted with an amine of the general formula (V) wherein  $R^1$  and  $R^2$  are as defined above.

the aldoxim derivatives of the general formula (VII) obtained according to any of the processes a) or b) wherein  $R^3$ ,  $R^4$ ,  $R^5$ , m and n are as defined above, after or without isolating, are reacted with inorganic acid chlorides or other halogenating agents and the hydroximic acid halides of the general formula (VIII) thus obtained are hydrolyzed in an aqueous-alkaline medium, directly or through the ester derivatives, or

c) an aldoxim derivative of the general formula (II) wherein the substituents are defined as above, is diazotized in the presence of  $\text{NaNO}_2$  and  $\text{HX}$  wherein X is as defined above and the diazonium salt thus obtained, without or after isolation, is subjected to "boiling away" reaction.

and, if desired, the free bases obtained during the reaction are transformed to the acid addition salt by reacting with organic or inorganic acids, or from the compounds obtained in the form of their salts the free bases are formed.

3. The process according to claim 2 characterized in that the reaction is carried out in a solvent.

4. The process according to claim 3 characterized in that as

- 21 -

solvent water, a mixture of water and an organic solvent or a mixture containing an aqueous and an organic solvent phase is used.






5. The process according to any of claims 2 to 4 characterized in that the reaction is carried out at a temperature of -10 to +140°C.

6. The compounds of the general formula (VIII) wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, X, m and n are as defined in claim 1.

7. Pharmaceutical compositions preferably having special beta-blocking effect in case of diabetes, characterized by containing as active ingredient one or more of the compounds of the general formula (I).




8. The use of the compounds of the general formula (I) in the therapy of diabetes.

- 1 / 2 -





- 2 / 2 -



# INTERNATIONAL SEARCH REPORT

International Application No PCT/HU 89/00048

| <b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup><br>According to International Patent Classification (IPC) or to both National Classification and IPC<br>IPC <sup>5</sup> : C 07 C 251/58, C 07 D 295/08, 295/12, C 07 C 249/12<br>A 61 K 31/15   |  |                                     |   |  |                                     |                                      |  |                                 |                        |  |       |       |  |  |
|--|--|-------------------------------------|---|--|-------------------------------------|--------------------------------------|--|---------------------------------|------------------------|--|-------|-------|--|--|
| <b>II. FIELDS SEARCHED</b><br><div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched <sup>7</sup></div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="padding: 5px;">Int.Cl.<sup>5</sup></td> <td style="padding: 5px;">C 07 C 251/00, 249/00; C 07 D 295/00</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation<br/>to the Extent that such Documents are Included in the Fields Searched <sup>8</sup></div> <div style="text-align: center; padding: 10px 0;">AT</div>   |  |                                     | Classification System                                     | Classification Symbols   | Int.Cl. <sup>5</sup>                | C 07 C 251/00, 249/00; C 07 D 295/00 |  |                                 |                        |  |       |       |  |  |
| Classification System  | Classification Symbols   |                                     |   |  |                                     |                                      |  |                                 |                        |  |       |       |  |  |
| Int.Cl. <sup>5</sup>   | C 07 C 251/00, 249/00; C 07 D 295/00   |                                     |   |  |                                     |                                      |  |                                 |                        |  |       |       |  |  |
| <b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category <sup>10</sup></th> <th style="border-bottom: 1px solid black;">Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup></th> <th style="width: 10%; border-bottom: 1px solid black;">Relevant to Claim No. <sup>13</sup></th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">US, A, 4 308 399 (KALMAN TAKACS et al.)<br/>29 December 1981 (29.12.81), see columns 1-4.</td> <td style="text-align: center; vertical-align: top; padding: 5px;">(1-8)</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">AT, B, 355 554 (CHINOIN GYOGYSZER) 10 March 1980 (10.03.80), see claims 1-3; page 2, lines 1-45.</td> <td style="text-align: center; vertical-align: top; padding: 5px;">(1-8)</td> </tr> <tr> <td colspan="3" style="text-align: center; padding: 20px 0;">-----</td> </tr> </tbody> </table>   |  |                                     | Category <sup>10</sup>                                    | Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup> | Relevant to Claim No. <sup>13</sup> | A                                    | US, A, 4 308 399 (KALMAN TAKACS et al.)<br>29 December 1981 (29.12.81), see columns 1-4. | (1-8)                           | A                      | AT, B, 355 554 (CHINOIN GYOGYSZER) 10 March 1980 (10.03.80), see claims 1-3; page 2, lines 1-45. | (1-8) | ----- |  |  |
| Category <sup>10</sup>   | Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup> | Relevant to Claim No. <sup>13</sup> |   |  |                                     |                                      |  |                                 |                        |  |       |       |  |  |
| A  | US, A, 4 308 399 (KALMAN TAKACS et al.)<br>29 December 1981 (29.12.81), see columns 1-4.                       | (1-8)                               |   |  |                                     |                                      |  |                                 |                        |  |       |       |  |  |
| A  | AT, B, 355 554 (CHINOIN GYOGYSZER) 10 March 1980 (10.03.80), see claims 1-3; page 2, lines 1-45.               | (1-8)                               |   |  |                                     |                                      |  |                                 |                        |  |       |       |  |  |
| -----  |  |                                     |   |  |                                     |                                      |  |                                 |                        |  |       |       |  |  |
| <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>14</sup> Special categories of cited documents: <sup>14</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div> |  |                                     |   |  |                                     |                                      |  |                                 |                        |  |       |       |  |  |
| <b>IV. CERTIFICATION</b> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="text-align: center; padding: 5px;">02 January 1990 (02.01.90)</td> <td style="text-align: center; padding: 5px;">02 January 1990 (02.01.90)</td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">International Searching Authority</td> <td style="border-bottom: 1px solid black; padding: 5px;">Signature of Authorized Officer</td> </tr> <tr> <td style="text-align: center; padding: 5px;">AUSTRIAN PATENT OFFICE</td> <td style="text-align: center; padding: 5px;"></td> </tr> </table>  |  |                                     | Date of the Actual Completion of the International Search | Date of Mailing of this International Search Report  | 02 January 1990 (02.01.90)          | 02 January 1990 (02.01.90)           | International Searching Authority  | Signature of Authorized Officer | AUSTRIAN PATENT OFFICE |  |       |       |  |  |
| Date of the Actual Completion of the International Search  | Date of Mailing of this International Search Report  |                                     |   |  |                                     |                                      |  |                                 |                        |  |       |       |  |  |
| 02 January 1990 (02.01.90)   | 02 January 1990 (02.01.90)   |                                     |   |  |                                     |                                      |  |                                 |                        |  |       |       |  |  |
| International Searching Authority  | Signature of Authorized Officer  |                                     |   |  |                                     |                                      |  |                                 |                        |  |       |       |  |  |
| AUSTRIAN PATENT OFFICE   |  |                                     |   |  |                                     |                                      |  |                                 |                        |  |       |       |  |  |

Anhang zum internationalen Recherchenbericht über die internationale Patentanmeldung Nr.

In diesem Anhang sind die Mitglieder der Patentfamilien der im obengenannten internationalen Recherchenbericht angeführten Patentedokumente angegeben. Diese Angaben dienen nur zur Unterrichtung und erfolgen ohne Gewähr.

Annex to the International Search Report on International Patent Application No. PCT/HU 89/00048

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned International search report. The Austrian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Annexe au rapport de recherche internationale relatif à la demande de brevet international n°.

La présente annexe indique les membres de la famille de brevets relatifs aux documents de brevets cités dans le rapport de recherche internationale visé ci-dessus. Les renseignements fournis sont donnés à titre indicatif et n'engagent pas la responsabilité de l'Office autrichien des brevets.

| Im Recherchenbericht<br>angeführtes Patent-<br>dokument<br>Patent document cited<br>in search report<br>Document de brevet cité<br>dans le rapport<br>de recherche | Datum der<br>Veröffentlichung<br>Publication<br>date<br>Date de<br>publication | Mitglied(er) der<br>Patentfamilie<br>Patent family<br>member(s)<br>Membre(s) de la<br>famille de<br>brevets   | Datum der<br>Veröffentlichung<br>Publication<br>date<br>Date de<br>publication   |
|--|--|---|--|
| US-A - 4308399   | 29-12-81   | None  |  |
| AT-B - 355554  | 10-03-80   | AT-A - 8741/78<br>AT-B - 361457<br>AT-A - 6054/77<br>AU-B2- 521432<br>BE-A1- 858134<br>CA-A1- 1077506<br>CH-A - 630344<br>CS- P- 204008<br>CS- P- 204009<br>DD- C- 132433<br>DE-A1- 2738589<br>DK-A - 3797/77<br>DK-B - 150196<br>DK-C - 150196<br>ES-A5- 462346<br>ES-A1- 462346<br>FI-A - 772551<br>FI-B - 68396<br>FI-C - 68396<br>FR-A1- 2362845<br>FR-B1- 2362845<br>GB-A - 1582029<br>GR-A - 63623<br>HU- P- 177578<br>IL-A0- 52804<br>IL-A1- 52804<br>JP-A2-53050131<br>JP-B4-62016942<br>NO-A - 772958<br>NO-B - 144793<br>NO-C - 144793<br>PL- P- 106317<br>PL- P- 107628<br>SE-A - 7709482<br>SE-B - 435280<br>SE-C - 435280<br>SU- D- 730296<br>YU-A - 2023/77<br>YU-A - 2377/82 | 15-08-80<br>10-03-81<br>15-08-79<br>01-04-82<br>16-12-77<br>13-05-80<br>15-06-82<br>31-03-81<br>31-03-81<br>27-09-78<br>02-03-78<br>28-02-78<br>05-01-87<br>06-07-87<br>30-05-78<br>16-06-78<br>28-02-78<br>31-05-85<br>10-09-85<br>24-03-78<br>09-01-81<br>31-12-80<br>27-11-79<br>28-11-81<br>31-10-77<br>29-06-81<br>08-05-78<br>15-04-87<br>28-02-78<br>03-08-81<br>11-11-81<br>31-12-79<br>29-02-80<br>28-02-78<br>17-09-84<br>20-12-84<br>25-04-80<br>31-12-83<br>31-12-83 |

AT-B-355 554

10-03-80

|                |          |
|----------------|----------|
| AU-A1-28254/77 | 01-03-79 |
| NL-A - 7709276 | 01-03-78 |
| NZ-A - 188006  | 19-11-81 |
| AR-A1- 223196  | 31-07-81 |
| AR-A1- 227125  | 30-09-82 |
| AR-A1- 228023  | 14-01-83 |
| AR-A1- 231636  | 31-01-85 |
| AT-A - 5539/78 | 15-04-81 |
| AT-B - 364830  | 25-11-81 |
| AT-A - 5659/80 | 15-12-83 |
| AT-A - 5660/80 | 15-02-84 |
| AT-B - 375350  | 25-07-84 |
| AT-B - 375928  | 25-09-84 |
| AU-A1-38478/78 | 07-02-80 |
| AU-B2- 523324  | 22-07-82 |
| CA-A1- 1109072 | 15-09-81 |
| DD- C- 138318  | 24-10-79 |
| DE-CO- 2861987 | 30-09-82 |
| DK-A - 3395/78 | 02-02-79 |
| EP-A1- 574     | 07-02-79 |
| EP-B1- 574     | 04-08-82 |
| ES-A1- 472208  | 16-03-79 |
| FI-A - 782348  | 02-02-79 |
| FI-B - 68231   | 30-04-85 |
| FI-C - 68231   | 12-08-85 |
| HU-B - 182938  | 28-03-84 |
| IE-B - 47285   | 08-02-84 |
| IL-AO- 55253   | 29-09-78 |
| IL-A1- 55253   | 30-04-82 |
| IT-A - 1156885 | 04-02-87 |
| JP-A2-54027565 | 01-03-79 |
| NO-A - 782615  | 02-02-79 |

|                |          |
|----------------|----------|
| NO-B - 150082  | 07-05-84 |
| NO-C - 150082  | 15-08-84 |
| PL- D- 208772  | 04-06-79 |
| PL-B1- 117328  | 31-07-81 |
| PL-B1- 117334  | 31-07-81 |
| PL-B1- 117404  | 31-08-81 |
| PT-A - 68365   | 01-07-78 |
| US-A - 4323688 | 06-04-82 |
| ZA-A - 7804323 | 25-07-79 |

---